What is MapLight Therapeutics, Inc. 's R&D?

MapLight Therapeutics, Inc. (MPLT) reported R&D of $53.68M in Q1 2026.

How has MapLight Therapeutics, Inc. 's R&D changed year-over-year?

MapLight Therapeutics, Inc. 's R&D increased by 171.3% year-over-year, from $19.79M to $53.68M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

MapLight Therapeutics, Inc. MPLT R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

Neurocrine BiosciencesNBIX

$296.2M+12.5%

Acadia PharmaceuticalsACAD

$76.87M-1.8%

LBR

LB Pharmaceuticals Inc Common StockLBRX

$14.65M+328%

MeiraGTx Holdings plcMGTX

$31.98M-2.4%

Xenon PharmaceuticalsXENE

$88.51M+44.6%

Segments

By segment

See full

Clinical Trial$24.82M+1,180%

Employee Related$15.99M+127%

Chemistry Manufacturing And Controls Expenses$6.42M+62.2%

Preclinical Program$5.52M-9.2%

All Other Segments$933K+22.6%

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B+109%

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's R&D?: MapLight Therapeutics, Inc. (MPLT) reported R&D of $53.68M in Q1 2026.
How has MapLight Therapeutics, Inc. 's R&D changed year-over-year?: MapLight Therapeutics, Inc. 's R&D increased by 171.3% year-over-year, from $19.79M to $53.68M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.